Xgene Pharmaceutical
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Xgene develops multimodal conjugated molecules using proprietary linker technology to create safer, more effective therapies for chronic pain and neurological disorders.
OncologyImmunologyNeurology
Technology Platform
Proprietary linker technology that creates dual-acting conjugates combining two therapeutic molecules with modified absorption, pharmacokinetic, and metabolic characteristics for synchronized pharmacokinetics and dual-pathway targeting.
Opportunities
Addressing the global opioid crisis with non-opioid alternatives and expanding their conjugate technology platform into oncology and immunology beyond their current pain focus.
Risk Factors
Clinical development risks for novel conjugate molecules, competition in pain management therapeutics, and potential regulatory challenges for multimodal combination products.
Competitive Landscape
Competes with other biotechs developing non-opioid pain therapies and novel analgesic mechanisms; differentiation through proprietary conjugate technology enabling synchronized pharmacokinetics and dual-pathway targeting.